Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle and weight reduction programs, has begun patient studies of its proprietary metabolic health program, Miboko. The studies are being conducted with the National Health Service (“NHS”) in the United Kingdom. Miboko is the first metabolic tracking program integrating a noninvasive glucose sensor with a lifestyle app that includes recording of food and drink, educational content and an analytics platform. Users receive a metabolic score based on diet, exercise and their individual glucose response to their food intake. Along with the score, the platform also provides personalized recommendations to help users reduce weight and avoid serious health issues, such as heart disease and diabetes. According to the announcement, the program will be available without prescription and is designed specifically for users wanting to lose weight; it will be offered directly to consumers as well as to employers and insurers. “Use of glucose monitoring is becoming more widespread, not just in people with diabetes, but also with those who wish to use personalized data to aid in weight loss,” said Nemaura Medical CEO Dr. Faz Chowdhury in the press release. “Studies have shown that glucose response to diet and lifestyle habits can have a profound behavioral impact in helping people to modify their diet and exercise regimes. We are very excited, both with the response that we have had from participants and also the weight loss results that are being reported.”
To view the full press release, visit https://ibn.fm/Ewzsy
About Nemaura Medical Inc.
Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark-approved class IIb medical device, is a noninvasive and flexible continuous glucose monitor (“CGM”) that provides actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a premarket approval application (“PMA”) for sugarBEAT to the U.S. Food and Drug Administration (“FDA”). proBEAT combines noninvasive glucose data processed using artificial intelligence (“AI”) and a digital healthcare subscription service and has been launched in the United States as a general wellness product as part of NMRD’s BEAT diabetes program, which is currently undergoing pilot studies. Nemaura sits at the intersection of the global type 2 diabetes market, which is expected to reach nearly $59 billion by 2025, the $50-plus billion prediabetic market and the wearable health-tech sector for weight loss and wellness applications, which is estimated to reach $60 billion by 2023. For more information about the company, visit www.NemauraMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork